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Is there a rationale and role for long-acting anticholinergic
bronchodilators in asthma?
David Price1,2, Leonard Fromer3, Alan Kaplan4, Thys van der Molen5 and Miguel Román-Rodríguez6
Despite current guidelines and the range of available treatments, over a half of patients with asthma continue to suffer from poor
symptomatic control and remain at risk of future worsening. Although a number of non-pharmacological measures are crucial for
good clinical management of asthma, new therapeutic controller medications will have a role in the future management of the
disease. Several long-acting anticholinergic bronchodilators are under investigation or are available for the treatment of respiratory
diseases, including tiotropium bromide, aclidinium bromide, glycopyrronium bromide, glycopyrrolate and umeclidinium bromide,
although none is yet licensed for the treatment of asthma. A recent Phase III investigation demonstrated that the once-daily long-
acting anticholinergic bronchodilator tiotropium bromide improves lung function and reduces the risk of exacerbation in patients
with symptomatic asthma, despite the use of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs). This has prompted
the question of what the rationale is for long-acting anticholinergic bronchodilators in asthma. Bronchial smooth muscle
contraction is the primary cause of reversible airway narrowing in asthma, and the baseline level of contraction is predominantly set
by the level of ‘cholinergic tone’. Patients with asthma have increased bronchial smooth muscle tone and mucus hypersecretion,
possibly as a result of elevated cholinergic activity, which anticholinergic compounds are known to reduce. Further, anticholinergic
compounds may also have anti-inﬂammatory properties. Thus, evidence suggests that long-acting anticholinergic bronchodilators
might offer beneﬁts for the maintenance of asthma control, such as in patients failing to gain control on ICS and a LABA, or those
with frequent exacerbations.
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INTRODUCTION
Asthma affects over 300 million individuals worldwide, a ﬁgure
that is estimated to grow by 100 million by 2025.1 A chronic
inﬂammatory disease of the airways, asthma has multifactorial
pathophysiological causes and considerable heterogeneity in the
classiﬁcation of the disease by phenotype, aetiology, severity and
interventional control.
Current guidelines recommend stepwise management to gain
and maintain control, in which the clinical deﬁnition of full
‘control’ is daytime symptoms or use of reliever medication less
than twice a week, no limitations of activity, no nocturnal
symptoms and normal lung function.2 Furthermore, the American
Thoracic Society and the European Respiratory Society state that
any deﬁnition or measure of control must take into account the
management of a patient’s future risk.3 Thus, in clinical manage-
ment of asthma, consideration must be given to reducing the
frequency of exacerbations, preserving lung function, preventing
reduced lung growth in children and minimising the adverse
effects of any treatment.4
For those receiving low-dose inhaled corticosteroids (ICS),
current step-up treatment involves the addition of a long-acting
β2-agonist (LABA) or leukotriene receptor antagonist as
controller therapy. In patients unable to attain or maintain control
with ICS and LABA—those in Global Initiative for Asthma
treatment steps 3–5 (Figure 1)—upward titration of ICS
dose, leukotriene modiﬁers, sustained-release theophylline, oral
glucocorticosteroids and anti-immunoglobulin E (omalizumab)
are all further or alternative treatment options.2
Despite these guidelines and the wide range of therapies
available, poor control of current asthma symptoms, and of future
asthma exacerbations, continues to affect 450% of patients,5–9
with exacerbations placing signiﬁcant strain on their quality of life
and on health-care systems.10 Risk factors associated with future
exacerbations include previous exacerbations, poor control,
inhaler technique and adherence, co-morbid allergic rhinitis,
gastro-oesophageal reﬂux disease, psychological dysfunction,
smoking and obesity.10 The same factors, in addition to incorrect
diagnosis, poor choice of inhaler, variation in individual treatment
responses or genetic components, have been attributed to the
underlying poor control.11 There are a number of actions available
in the primary care setting to reduce the impact of these factors
(Figure 1).10,11
In the light of such concerns around risk and poor control, it is
appropriate to consider the rationale for investigating additional
controller medications. A number of new therapies are under
investigation,12 including long-acting anticholinergic bronchodi-
lators (the focus of this review), anti-prostaglandin D2 CRTH2
antagonists,13 phosphodiesterase-4 inhibitors,5 anti-leukotriene 5-
lipoxygenase-activating protein antagonists14 and the monoclonal
antibodies mepolizumab and lebrikizumab (which are raised
against interleukin-515 and interleukin-13,16 respectively).
Short-acting anticholinergic agents, particularly ipratropium
bromide (ipratropium) and oxitropium bromide (oxitropium), have
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been used in asthma for many years,17,18 although they have not
become widespread because they are generally considered to be
less effective than short-acting β2-agonists (SABAs) for acute
bronchodilation.17 This, coupled with a perception that longer-
term antagonism of cholinergic receptors induces little broncho-
dilation above that induced by LABAs,19,20 has meant that, in
contrast to chronic obstructive pulmonary disease,21,22 long-acting
anticholinergic bronchodilators have not been considered or
thoroughly investigated as potential controller medication in
asthma. Early studies demonstrated mild bronchodilation and
protection, over 48 h, against methacholine-induced bronchocon-
striction in male patients with asthma,23 and, in patients with
severe persistent asthma, small improvements in lung function
were observed with the LABA salmeterol plus the long-acting
anticholinergic bronchodilator tiotropium bromide (tiotropium),
with a halved dose of ﬂuticasone propionate.24
Recently, Phase I–III clinical investigation with long-acting
anticholinergic bronchodilators in asthma has begun: two Phase
II trials of umeclidinium bromide (umeclidinium) have completed
(NCT01641692; NCT01573624), and Phase II and III trials with
tiotropium, as add-on therapy, have demonstrated improvements
in lung function and a reduction in exacerbation risk in patients
with poorly controlled asthma despite the use of ICS or ICS plus a
LABA.25–28
In this review, we consider the pathophysiological and clinical
rationales for use of long-acting anticholinergic agents in the
broader management of asthma, and the clinical evidence
reported to date. Please see Box 1 for a description of the
literature search and appraisal methods.
THE ROLE OF CHOLINERGIC ACTIVITY IN THE
PATHOPHYSIOLOGY OF ASTHMA
The symptoms of asthma, and of acute exacerbations, are
attributed to airway narrowing that occurs as a consequence of
chronic inﬂammation and associated hyper-responsiveness.2 Local
inﬂux of inﬂammatory cells and high levels of inﬂammatory
mediators result in airway oedema, airway thickening, mucus
hypersecretion and bronchial smooth muscle contraction
(Table 1).2 Although multiple pathophysiological mechanisms
are thought to contribute to the characteristic narrowing of
airways and the hyper-responsiveness found in asthma (Table 1),2
bronchial smooth muscle contraction represents the primary
cause of reversible airway obstruction in asthma.29,30 The degree
of basal airway smooth muscle contraction (airway smooth muscle
‘tone’) is under autonomic nervous regulation (Figure 2), although
the mechanisms are not fully understood. During normal
ventilation, adrenergic sympathetic nerves and parasympathetic
cholinergic and non-cholinergic nerves are all active,29,31,32 but
cholinergic activity is thought to be the predominant driver of
bronchoconstriction (Figure 2, Box 2).31 Acute treatment with the
anticholinergic compounds atropine and ipratropium is known to
reduce basal airway smooth muscle tone.33,34
Patients with asthma have increased basal airway smooth
muscle tone,35 and there is evidence to suggest that this is a result
of increased basal activity of pulmonary parasympathetic choli-
nergic nerves, hereinafter described as ‘cholinergic tone’. Molﬁno
et al.30 demonstrated that bronchoconstriction induced by breath-
holding is signiﬁcantly inhibited by ipratropium in asthmatic
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Figure 1. Combined approaches for the management of control in asthma.2,5,10–16 FLAP, 5-lipoxygenase-activating protein; ICS, inhaled
corticosteroids; IL, interleukin; LABA, long-acting β2-agonist; PDE4, phosphodiesterase-4; SABA, short-acting β2-agonist.
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patients but not in healthy volunteers. It is thought that
cholinergic tone, at least, is driven by afferent nervous activity
arising in the airways,29,36,37 and it has been hypothesised that
local airway inﬂammatory mediators may have a role in inducing
afferent activity and an autonomic reﬂex response, thereby driving
an increase in cholinergic tone (Figure 2).31,38,39 Other proposed
mechanisms for increased cholinergic tone in asthmatic patients
include abnormal muscarinic receptor expression,40 increased
release of acetylcholine from cholinergic nerve endings41 and
reduced levels of neuromodulators that attenuate cholinergic
neurotransmission.42,43
The degree to which cholinergic tone contributes to airway
narrowing in asthma, either at basal state or during exacerbations,
is unclear. However, the fact that airway hyper-responsiveness can
persist in asthmatic patients, possibly even in the absence of
airway inﬂammation following long-term ICS use,44 suggests that
other pathophysiological factors, such as increased cholinergic
and smooth muscle tone, have a role in asthma.39,45 It has been
proposed that acetylcholine has a prominent role in allergen-
induced airway smooth muscle remodelling.46–48 In a guinea pig
model of ongoing allergic asthma, treatment with tiotropium
inhibited increases in airway smooth muscle mass and contractility
induced by allergic challenge; it has thus been hypothesised that
Table 1. Mechanisms of airway narrowing and hyper-responsiveness
in asthma2
Process Consequence
Increased volume and/or
contractility of airway smooth
muscle cells
Excessive contractility of airway
smooth muscle
Secretion of multiple
bronchoconstriction mediators
such as histamine, prostaglandin
D2 and neurotransmitters
Airway smooth muscle
contraction
Uncoupling of airway smooth
muscle contraction as a result
of inﬂammatory changes in
the airway wall
Excessive narrowing of the
airways; loss of maximum plateau
of contraction when a
bronchodilator is administered
Oedema due to microvascular
leakage in response to
inﬂammatory mediators and
structural changes to airway
smooth muscle
Thickening of airway wall;
ampliﬁcation of airway narrowing
due to contraction of airway
smooth muscle for geometric
reasons
Sensitisation of sensory nerves
leading to afferent activity and
autonomic reﬂex
Increased parasympathetic,
cholinergic and airway smooth
muscle tone, with consequent
exaggerated bronchoconstriction
in response to sensory stimuli
Box 1 Literature evaluation methods
Clinical evidence around long-acting anticholinergic broncho-
dilators
We performed searches in November 2013 of PubMed, Google
Scholar and Cochrane databases and ClinicalTrials.gov (www.
clinicaltrials.gov).
PubMed searches
All terms restricted to title and abstract, with restriction of results
to clinical trials:
● (1) Asthma* AND (anticholinergic OR antimuscarinic OR
cholinergic OR muscarinic OR parasympathetic)
● (2) Asthma* AND (tiotropium OR umeclidinium OR aclidi-
nium OR glycopyrronium OR darotropium OR QVA149 OR
glycopyrrolate)
● In November 2013 the searches yielded 209 results; search
2 yielded 25 results. PubMed search results were manually
reviewed for articles or studies relevant to the topic of
short-acting muscarinic agonists or long-acting muscarinic
agonists for acute or maintenance therapy
Cochrane database searches
● ‘Asthma AND anticholinergic’, limited to title, abstract and
keywords, yielding 39 hits, the titles and abstracts of which
were manually reviewed
● In November 2013 the searches yielded one review19
relating to the use of anticholinergics for asthma manage-
ment, and eight reviews of anticholinergics in a variety of
acute settings
www.clinicaltrials.gov searches
● Asthma AND tiotropium OR umeclidinium OR aclidinium
OR glycopyrronium OR darotropium OR glycopyrrolate
OR QVA149
Pathophysiology and pharmacology
PubMed and Google scholar searches
● The following terms in Boolean strings: asthma; respiratory;
cholinergic; muscarinic; parasympathetic; autonomic; tone;
pathophysiology; anticholinergic; antimuscarinic; β-agonist;
phenotype; genotype; inﬂammation; bronchoconstriction;
and bronchodilation
● As this article is not a systematic review, certain articles
within the pathophysiology and pharmacology sections
were reviewed and cited based on their adjudged relevance
to the topic
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Figure 2. Autonomic regulation of airway smooth muscle
tone.29,32,49,50 M1, M2, M3, muscarinic acetylcholine receptors 1, 2
and 3. + and − symbols represent signals increasing and decreasing
airway smooth muscle tone, respectively. Note that non-adrenergic
non-cholinergic autonomic pathways have been omitted for
simplicity. Adapted from the study by Cazzola, et al.,32 with
permission from the American Society for Pharmacology and
Experimental Therapeutics.
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anticholinergic drugs could help prevent airway smooth muscle
remodelling in human asthma.17
Cholinergic activity is also believed to regulate non-smooth
muscle and non-neuronal cells within the lungs, including
inﬂammatory cells and those controlling mucus secretion.49,50 In
a guinea pig model, tiotropium was shown to reduce allergen-
induced mucus gland hypertrophy and goblet cell number,50
suggesting that anticholinergic bronchodilators might also reduce
airﬂow obstruction by reducing mucus hypersecretion. Expression
of cholinergic receptors on inﬂammatory cells raises the additional
question of whether there are any non-neuronal anti-inﬂamma-
tory actions of cholinergic antagonists, although a review of
studies on chronic obstructive pulmonary disease failed to identify
robust evidence of this.51
PHARMACOLOGY OF ANTICHOLINERGIC BRONCHODILATORS
Anticholinergic bronchodilators are antagonistic to parasympa-
thetic activity and exert their effects on acetylcholine receptors on
airway smooth muscle and pulmonary parasympathetic nerves
(Figure 2). Acetylcholine receptors fall into two families—nicotinic
and muscarinic—and it is the M1, M2 and M3 subtypes of the latter
that are thought to be primarily involved in the regulation of
bronchoconstriction.17 All subtypes of muscarinic receptors are
widely expressed in the brain, the parasympathetic nervous
system and the body’s smooth muscle tissues. M1 receptors are
broadly distributed throughout the parasympathetic ganglia and
regulate cholinergic transmission. M2 receptors are found in
prejunctional membranes of neuromuscular junctions of airway
smooth muscle and regulate negative feedback to reduce
acetylcholine transmission. In a pulmonary context, M3 receptors
are predominantly expressed in smooth muscle cells, where they
regulate contraction, and also within lung submucosal glands,
where they regulate mucus secretion52 (Figure 2). Thus, it is
preferable for antimuscarinic bronchodilators to have a relatively
high afﬁnity for M1 and M3 receptors and low afﬁnity for the M2
receptor.17
Currently, there are ﬁve anticholinergic drugs available for
bronchodilation in respiratory disease. Ipratropium and oxitro-
pium are short-acting non-selective antagonists of M1, M2 and
M3 receptors.
53 In contrast, tiotropium, aclidinium bromide
(aclidinium) and glycopyrronium bromide (glycopyrronium) are
long-acting compounds, with comparative selectivity for the
M1/M3, M2/M3 and M3 receptors, respectively.
17,53,54
Short-acting anticholinergics are generally considered less
effective acute bronchodilators than SABAs, and their short
duration of action makes them broadly unsuitable as controller
medication. Thus, evidence of increased cholinergic tone in
patients with asthma indicates that the longer-acting bronchodi-
lator compounds may be more suitable as controller medications
in asthma.
There is some rationale to suggest that the addition of long-
acting anticholinergic bronchodilators to LABAs might provide
advantages in the treatment of asthma (Box 2). It is reasonable to
hypothesise that by simultaneously antagonising parasympathetic
smooth muscle contraction and stimulating adrenergic smooth
muscle relaxation, it is possible to achieve greater bronchodilation
compared with either strategy in isolation. To date, there has
been little thorough clinical investigation of this hypothesis in
asthma, but a study in a guinea pig model found that
bronchodilation induced by the LABA carmoterol was signiﬁcantly
augmented by the addition of tiotropium.55 In vitro studies
have also found that the LABA indacaterol can synergistically
increase the inhibitory effects of glycopyrronium on
methacholine-induced airway smooth muscle contraction.56 As
discussed below, improvements in lung function have been
observed in asthmatic patients receiving tiotropium as add-on
therapy to LABA plus ICS.26,28
It has been suggested that anticholinergic/LABA combination
therapy might offer advantages in mitigating daily variation,
based on evidence that sympathetic activity may be elevated
during the daytime, relative to the parasympathetic system, which
may predominate at night.57–60 For example, it was shown in a
small study in patients with nocturnal asthma that ipratropium is
more effective than salbutamol in the prevention of morning
reductions in peak expiratory ﬂow.59 It is also possible that a
combined approach to bronchodilation might reduce the impact
of inter-patient variability in the relative responses to anti-
cholinergic or adrenergic interventions. Finally, tachyphylaxis to
the effects of β-agonists is known to occur (although the clinical
relevance of this remains unclear),61–63 and it has been proposed
that crosstalk between muscarinic receptor signalling and
adrenergic receptor signalling in smooth muscle cells might
interfere with tachyphylactic mechanisms. This would provide a
further rationale for the investigation of LABA/long-acting anti-
cholinergic bronchodilator combination therapy in asthma, as
add-on to ICS.64
CLINICAL EVIDENCE OF ANTICHOLINERGIC
BRONCHODILATORS IN ASTHMA
Historically, short-acting anticholinergic bronchodilators have not
been considered appropriate for the control of asthma, except in
some cases for the acute treatment of asthma attacks in patients
with chronic stable asthma,17,18 and in those who experience
adverse events from SABAs, such as tachycardia, arrhythmia and
tremor.1,43 Although short-acting anticholinergics are considered
less effective rapid bronchodilators than SABAs such as
salbutamol,17,19 there are data to suggest that, for acute
exacerbations, ipratropium in combination with a SABA as reliever
medication improves lung function to a greater extent than a
SABA alone.34,65,66 In a double-blind, randomised trial, Rodrigo
and Rodrigo65 investigated the effects of high-dose ipratropium
plus the SABA albuterol (registered generic name for salbutamol
in the USA) in adults with acute asthma, in the emergency
Box 2 Possible pathophysiological reasons why long-acting anti-
cholinergic bronchodilators may be beneﬁcial for the control of asthma
● Cholinergic activity is the predominant driver of bronchial
smooth muscle contraction, the primary cause of reversible
airway obstruction in asthma29–31
● Patients with asthma have increased basal airway smooth
muscle tone, possibly as a result of increased cholinergic
tone30,35
● Acute treatment with anticholinergic compounds reduces
basal airway smooth muscle tone33,34
● Local airway inﬂammatory mediators may have a role in
inducing increased cholinergic tone29,31,36–39
● Cholinergic activity may have a prominent role in airway
smooth muscle remodelling17,46,47
● Cholinergic receptors on lung submucosal cells regulate
mucus secretion49,50,52
● Increased cholinergic and smooth muscle tone may con-
tribute to airway hyper-responsiveness39,44,45
● Cholinergic antagonists may have non-neuronal anti-inﬂam-
matory actions51
● Patients with asthma may have abnormal muscarinic
receptor expression40
● Patients with asthma may have increased release of
acetylcholine from cholinergic nerve endings41
● Patients with asthma may have reduced levels of neuro-
modulators that attenuate cholinergic neurotransmission42,43
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department. Patients receiving high-dose ipratropium plus albu-
terol had a greater improvement in peak expiratory ﬂow and
forced expiratory volume in 1 s compared with patients who
received albuterol alone. The risk of hospital admission was 49%
lower in the ipratropium/albuterol arm.65 Further, a meta-analysis
has indicated that the addition of a short-acting anticholinergic to
a SABA is associated with a signiﬁcant reduction in the risk of
hospitalisation in children.67 Thus, in adults or children, the main
justiﬁcation for the use of short-acting anticholinergic drugs in
acute asthma is reduction of the elevated airway smooth muscle
and cholinergic tone during an acute crisis, although administra-
tion of multiple doses has been associated with a reduction in
hospitalisations and risk of hospitalisation.34,65–68
Although tiotropium has been indicated for the treatment of
chronic obstructive pulmonary disease for over a decade, no long-
acting anticholinergic bronchodilators are currently approved in
asthma. A number of compounds exist, including aclidinium,
glycopyrronium, glycopyrrolate and darotropium bromide, but, as
mentioned, presently only tiotropium and umeclidinium have
clinical trials in asthma listed on ClinicalTrials.gov. The latter has
been under investigation in two dose-ranging Phase II trials in
patients with asthma, as a monotherapy (NCT01641692) and in
combination with ﬂuticasone furoate (NCT01573624), although to
our knowledge no results from these trials have yet been
published.
Early studies with long-acting anticholinergics in asthma were
small and underpowered, and failed to detect meaningful
responses. However, studies of tiotropium and of glycopyrrolate
indicated that long-acting anticholinergics can provide sustained
bronchodilation and bronchoprotection.23,24,69,70
To date, more thorough clinical evaluation has been performed
with tiotropium only, in six Phase II or III studies, involving over
3,500 patients (Table 2). In an investigator-initiated three-way
crossover trial (14 weeks per treatment) in 210 patients with
asthma inadequately controlled by low-dose ICS (twice-daily
beclomethasone 80 μg), tiotropium delivered via the Spiriva
HandiHaler device (Boehringer Ingelheim Pharmaceuticals, Ridge-
ﬁeld, CT, USA) was shown to be superior to a doubling of ICS dose
and equal to the addition of salmeterol, as assessed by
improvements in lung function (Table 2).27
Subsequent published investigations of tiotropium have all
involved administration via the Respimat SoftMist inhaler (Boeh-
ringer Ingelheim Pharma, Ingelheim am Rhein, Germany). In an 8-
week crossover trial, once-daily tiotropium at a dose of 5 or 10 μg
improved lung function, compared with placebo, in 107 patients
with severe persistent poorly controlled asthma already receiving
ICS and LABA (Table 2).26 In a 16-week trial in patients with
arginine/arginine homozygosity at amino acid 16 of the β2-
adrenergic receptor (B16-Arg/Arg) and moderate poorly con-
trolled asthma (already receiving ICS), once-daily tiotropium at a
dose of 5 μg was superior to placebo and non-inferior to twice-
daily salmeterol at a dose of 50 μg for maintenance of
improvements in lung function (Table 2).25 The rationale for
performing the latter study was based on suggestions that the
adverse-event proﬁle of β2-agonists is worse, and the efﬁcacy
lower, in patients with the B16-Arg/Arg polymorphism,71,72
although prospective investigation has revealed that there are
no such concerns.73,74 A subsequent Phase II dose-ranging study
tested tiotropium at doses of 5 μg, 2.5 μg and 1.25 μg as add-on to
ICS and found the 5 μg dose to provide the greatest bronchodi-
lator effect.75
Data from the ﬁrst Phase III trial on a long-acting anticholinergic
bronchodilator in asthma were published in 2012.28 In two
replicate trials including a total of 912 patients with poorly
controlled asthma despite the use of LABA and high-dose ICS
(⩾800 μg budesonide or equivalent), tiotropium 5 μg administered
via the Respimat SoftMist inhaler as add-on therapy signiﬁcantly
reduced the risk of severe exacerbations compared with placebo
(values provided in Table 2). Small but statistically signiﬁcant
improvements in lung function were also observed.28 Surprisingly,
given the changes in lung function and exacerbation rate,
improvements in symptomatic beneﬁt (seven-question Asthma
Control Questionnaire [ACQ-7] and Asthma Quality of Life
Questionnaire) were small and inconsistent. Of adverse events
reported in ⩾ 2% of patients, only allergic rhinitis occurred at a
statistically signiﬁcantly higher rate in the tiotropium group
compared with the placebo group. Dry mouth, a typical side
effect associated with anticholinergic drugs, was reported in ⩽ 2%
of patients.28
More recently, a Phase III replicate trial of once-daily tiotropium
at a dose of 5 or 2.5 μg, versus placebo, as add-on to medium-
dose ICS (400–800 μg budesonide or equivalent) was conducted
in 2,103 patients with poorly controlled asthma.76,77 An active
comparator arm of salmeterol 50 μg versus placebo was also
included. Again, statistically signiﬁcant improvements in lung
function were observed with tiotropium, which were comparable
in magnitude with those seen with salmeterol. A statistically
signiﬁcant improvement over placebo in ACQ-7 responder rate
was observed in all three active arms, although, as is common in
analyses of ACQ-7 in asthma clinical trials,78 there was also a large
placebo effect.76,77 We await the full primary publication from
this trial.
IS THERE A ROLE FOR LONG-ACTING ANTICHOLINERGIC
BRONCHODILATORS IN ASTHMA?
Is it possible to determine to which patients, and in which clinical
situations, long-acting anticholinergic bronchodilators might offer
clinical beneﬁts? Phase III investigation has found that tiotropium
add-on therapy offers advantages to adults with severe asthma
who are failing to gain control on ICS and LABA combinations.28
This, and the fact that the beneﬁt:risk ratio of ICS falls at high ICS
doses,2,7,17,79,80 suggests that addition of long-acting anticholiner-
gic bronchodilators to ICS plus a LABA is likely to be a useful
option for patients with poorly controlled severe asthma, and an
alternative to further increases in ICS dose.
Whether long-acting anticholinergics will be appropriate as
alternatives to LABAs is a harder question to answer. Nevertheless,
tiotropium add-on to medium-dose ICS has been shown to
provide lung function and ACQ-7 improvements that were
comparable with those of salmeterol,76,77 indicating that, in
patients for whom LABAs may be unsuitable, long-acting antic-
holinergics could be a helpful alternative.
Although the ACQ-7 effects reported in clinical trials thus far are
relatively small, it will be interesting to see to what extent in
practice patients gain clinically relevant beneﬁts in control or
future risk. Further, one might expect that the demonstrated
reduction of exacerbation risk with tiotropium as add-on to ICS
plus LABA28 might translate into long-term improvements in
overall control. We anticipate that lung function improvements of
the magnitude observed in the trials we have described will
translate into clinically relevant beneﬁts to patients in a real-world
setting. At the time of writing, few real-world studies have been
performed, as long-acting anticholinergic bronchodilators are yet
to be approved in asthma. However, in a retrospective study of the
UK Optimum Patient Care Research Database, off-label use of
tiotropium in patients predominantly in Global Initiative for
Asthma step 3 or 4 was found to be associated with a reduction
in the number of exacerbations and a reduced risk of severe
exacerbation or lower respiratory tract infection.81
It is yet to be determined in Phase III investigation whether
long-acting anticholinergic bronchodilators offer similar beneﬁts
to adults with mild asthma or to children or adolescents, although
several Phase III trials are underway with tiotropium in
these populations (NCT01316380; NCT01634139; NCT01634152;
NCT01277523).
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There are some physiological (Box 2) and clinical rationales that
allow us to suggest groups of patients for whom long-acting
anticholinergic bronchodilators might be appropriate. A few small
studies with short-acting anticholinergic bronchodilators have
indicated that responses to anticholinergics are more likely in older
patients82,83 or in those with intrinsic (non-allergic) asthma.84 It has
also been suggested that patients intolerant of β2-adrenergic
agents or with nocturnal asthma might respond better to
anticholinergic bronchodilators.17 Further, there is evidence that
patients with non-eosinophilic sputum proﬁles85,86 or neutrophilic
inﬂammation do not gain the same beneﬁt from ICS as those with
eosinophilic inﬂammation,87 and hence may be candidates for
additional treatments such as long-acting anticholinergic bronch-
odilators, as may groups in which steroid resistance is known to
occur, such as smokers or obese patients.88,89
It is currently unclear why long-acting anticholinergic
bronchodilators might reduce the rate of exacerbations.
However, one can hypothesise that a contributing factor to
Table 2. Comparison of lung function and clinical ﬁndings from clinical trialsa with long-acting anticholinergic bronchodilators in asthma
Authors Severity b Duration per
treatment,
weeks
N Study drug(s) Comparator(s) Primary and key
secondary end points
Difference from
comparator c
Peters
et al.27
Mild to moderate
asthma
inadequately
controlled by
low-dose ICS
14 210 Once-daily
tiotropium 18 μg, via
Spiriva HandiHaler
Doubling
ICS dose
Morning PEF 25.8 l/min (95% CI:
14.4–37.1; Po0.001)
Doubling
ICS dose
Daily symptom
score
− 0.11 points (Po0.001)
Salmeterol Morning PEF No signiﬁcant difference
Salmeterol Daily symptom score No signiﬁcant difference
Kerstjens
et al.26
Severe asthma
inadequately
controlled by high-
dose ICS + LABA
8 107 Once-daily
tiotropium 5 μg, via
Respimat SoftMist
Placebo Tiotropium 5 μg,
peak FEV1
139ml (95% CI: 96–181;
Po0.0001)
Asthma-related
health status or
symptoms
No signiﬁcant difference
Once-daily
tiotropium 10 μg, via
Respimat SoftMist
Tiotropium 10 μg,
peak FEV1
170ml (95% CI: 128–213;
Po0.001)
Asthma-related
health status or
symptoms
No signiﬁcant difference
Bateman
et al.25
Mild to moderate
asthma
uncontrolled by
ICS alone
16 38 Once-daily
tiotropium 5 μg, via
Respimat SoftMist
Placebo
(following run-in
with salmeterol)d
Morning
pre-dose
PEF
− 20.70 l/min (95% CI:
− 33.24 to − 8.16;
P= 0.001 for superiority)
Salmeterol
(following run-in
with salmeterol)
d
Morning
pre-dose
PEF
− 0.78 l/min (95%
CI: −13.096 to 11.530;
P= 0.002 for
non-inferiority)
Kerstjens
et al.28
Poorly controlled
asthma despite use
of ICS + LABA
48 912 Once-daily
tiotropium 5 μg, via
Respimat SoftMist
Placebo Peak FEV1
at week 24
86± 34ml (P= 0.01)
(trial 1); 154± 32ml
(Po0.001) (trial 2)
Trough FEV1
at week 24
88± 31ml (P= 0.01)
(trial 1); 111± 30ml
(P= 0.001) (trial 2)
Reduction in risk of
severe exacerbation
at week 48
21% (hazard ratio 0.79;
Po0.03) (pooled
population)
Difference in AQLQ 0.04 units, NS (trial 1)e
0.18 units, P= 0.02
(trial 2)e
Difference in ACQ-7 − 0.13, NS (trial 1)e
− 0.2, P= 0.003 (trial 2)e
Abbreviations: ACQ-7, seven-question Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CI, conﬁdence interval; FEV1, forced
expiratory volume in 1 s; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; NS, not signiﬁcant; PEF, peak expiratory ﬂow.
aOnly studies published in journal primary publication format have been included (Kerstjens et al.76,77 and Beeh et al.75 not shown).
bAll studies were in adults.
cAll lung function values are mean change from baseline, unless otherwise stated.
dActive treatments were evaluated as maintenance therapies following a 4-week run-in period with salmeterol.
eMinimal clinically important difference not achieved.
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exacerbations might be an increase in afferent sensory
nerve activity, resulting in an increase in parasympathetic
tone and subsequent bronchoconstriction. If this were the
case, treatment with long-acting anticholinergic therapies
may attenuate such autonomic effects and provide additional
bronchodilation.
CONCLUSIONS
It has long been apparent from clinical and preclinical investiga-
tions of the pathophysiology of asthma that cholinergic para-
sympathetic tone contributes to contraction of bronchial smooth
muscle and narrowing of the airways. The extent to which
increased parasympathetic tone is a consequence of reﬂex to the
inﬂammatory state or is a pathophysiological mechanism in itself
is unclear. Regardless, the raised parasympathetic tone does
provide a rationale for the use of long-acting anticholinergic
bronchodilators in asthma, and recent Phase III trial results have
demonstrated clinical beneﬁts and lung function improvements
with tiotropium as add-on therapy to ICS alone or ICS plus LABA in
adult patients with poorly controlled asthma. In light of the
evidence, we believe that anticholinergic bronchodilators will be a
useful add-on therapy for patients at high risk of future worsening
or exacerbations, and in patients whose asthma remains
uncontrolled on a broad range of treatments and/or for whom
other alternative therapies are unsuitable.
Whether tiotropium or other long-acting anticholinergic
bronchodilators will offer clinical advantages in younger patients,
or in those with less severe asthma than studied thus far, is under
investigation. As we gain clinical experience in asthma with long-
acting anticholinergics, if approved, it will be interesting to see
whether and to what extent certain subgroups and phenotypes
beneﬁt from their use as controller medications.
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